Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine

Journal of Infectious Diseases

Volumn 183, Issue 7, 2001, Pages 1116-1120

  Jankelevich, Shirley ^a   Mueller, Brigitta U ^a   Mackall, Crystal L ^b   Smith, Sharon ^a   Zwerski, Sheryl ^a   Wood, Lauren V ^a   Zeichner, Steven L ^a   Serchuck, Leslie ^a   Steinberg, Seth M ^c   Nelson, Robert P ^d   Sleasman, John W ^e   Nguyen, Bach Yen ^f   Pizzo, Philip A ^a   Yarchoan, Robert ^a  

^a HIV and AIDS Malignancy Branch   (United States)

^b Neuro Oncology Branch   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIGENS, CD4; ANTIGENS, CD45; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LAMIVUDINE; MALE; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0035312995     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/319274     Document Type: Article

References (15)

1. +T-lymphocyte regeneration after intensive chemotherapy
2. A phase I/II study of the protease inhibitor indinavir in children with HIV infection
3. +T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
4. A network algorithm for performing Fisher's exact test in r × c contingency tables
5. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age
6. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
7. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
8. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
9. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
10. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency
11. +T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
12. Protease inhibitor and triple-drug therapy: Cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment
13. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
14. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events
15. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo